Valeritas (NSDQ:VLRX) today announced positive results from its preclinical pharmacokinetic study of cannabidiol subcutaneous infusion.
The study focused on delivering cannabidiol (CBD) through subcutaneous infusion through the company’s h-Patch Wearable Device. The results were presented at the CannMed Conference in Pasadena, Calif.
Results from the study showed rapid and robust absorption and distribution of 40mg of CBD delivered over a 24 hour period using the h-Patch technology.
Get the full story on our sister site, Drug Delivery Business.